DNA methylation mediated silencing of microRNA-145 is a potential prognostic marker in patients with lung adenocarcinoma

Wenjie Xia1,2,*, Qiang Chen2,3,*, Jie Wang1, Qixing Mao1,2, Gaochao Dong1, Run Shi1,2, YanYan Zheng1, Lin Xu1 & Feng Jiang1

The molecular mechanism of down-regulated microRNA-145 (miR-145) expression in lung adenocarcinoma (LAC) remains largely unknown. We hypothesized that aberrant hyper-methylation of the CpG sites silenced the expression of miR-145 in LAC. In consideration of its pivotal role in LAC development and progression, we also evaluated the clinical utility of miR-145 as a prognostic marker. We assessed the DNA methylation status of the miR-145 promoter region in 20 pairs of LAC and the matched non-tumor specimens. We subsequently applied our own LAC tissue microarray containing 92 pairs of tumor and non-tumor tissues with long time follow-up records to evaluate whether miR-145 is a potential prognostic marker in LAC. The Sequenom EpiTYPER MassArray analysis showed that miR-145 was down-regulated in human LAC tissues accompanied by increased DNA methylation of its upstream region, which was further validated by the data from TCGA database. Significance was observed between miR-145 expression and clinic-pathologic parameters. Univariate and multivariate analysis revealed that miR-145 expression level was an independent risk factor for both OS and DFS in LAC patients. Taken together, DNA hyper-methylation in the miR-145 promoter region reduced its expression in LAC and miR-145 expression level might serve as a novel prognostic biomarker.

With approximately 1.5 million new cases diagnosed every year, lung cancer is the most prevalent cause of cancer deaths worldwide and lung adenocarcinoma (LAC) accounts for almost 40% of lung cancer deaths1,2. Already recognized as crucial factors in tumorigenesis, microRNAs (miRNAs) are proposed as promising biomarkers for early cancer detection and accurate prognosis as well as targets for more efficient treatment3–6. Recently, microRNA-145 (miR-145) was identified as a tumor-suppressive miRNA that was down-regulated in several cancer types, including prostate cancer, bladder cancer, colon cancer and ovarian cancer7–12.

Our previous study demonstrated that miR-145 was down-regulated in LAC tissues and miR-145 could suppress the proliferation of lung cancer-initiating cells (LCICs) derived from A549 in vitro by targeting Oct4 mRNA13. Our following study further validated that miR-145 could also modulate the epithelial-mesenchymal transition (EMT) properties of LAC cells by targeting Oct413,14. By now, miR-145 was also reported to be involved in tumor progression by targeting c-Myc, AEG-1, EGFR, and NUDT1 in LAC15–17. Therefore, downstream mechanisms of miR-145 altering cellular processes

1Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing, P.R. China, 210009. 2The Fourth Clinical College of Nanjing Medical University, Nanjing 210000, China. 3Department of Thoracic Surgery, Xuzhou Centre Hospital. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to L.X. (email: xulin_83@hotmail.com) or F.J. (email: zengnjljf@hotmail.com)
are partially confirmed. In our present study we aim to explore the upstream molecular mechanism of down-regulated miR-145 expression in LAC.

It was suggested in recent studies that epigenetic alteration was involved in the dysregulation of miRNAs, especially, the hyper-methylation of CpG islands in the miRNA promoter region could lead to down-regulation of miRNAs in various cancers. We hypothesized that aberrant hyper-methylation of the CpG sites in the miR-145 promoter region reduced its expression level in LAC. In the present study we carried out experiments in both LAC cell lines and the freshly resected LAC tissues to verify our hypothesis. And we also applied The Cancer Genome Atlas (TCGA) database to further validate our finding.

In view of its pivotal role in tumor development and progression, we also explored the clinical utility of miR-145 as a prognostic marker. We applied our own tissue microarray (TMA) containing 92 pairs of tumor and non-tumor tissues with long time follow-up records to investigate the association of miR-145 expression with clinic-pathological parameters, as well as the correlation between miR-145 expression and disease-free survival (DFS) and overall survival (OS) in LAC.

**Results**

**Aberrant CpG methylation down-regulates the expression level of miR-145 in LAC.** As shown in Fig. 1A, pretreatment with 5-aza-2-deoxycytidine for 3 or 7 days led to remarkably elevated miR-145 expression, indicating that there was a reverse correlation between DNA methylation and miR-145 expression. Subsequently, DNA methylation level of 13 CpG sites (which were divided into 10 CpG units) upstream of the miR-145 gene location were assessed using Sequenom Epityper MassArray in 20 paired LAC and their matched para-tumor tissues. The results showed that all of the 13 CpG sites located upstream of miR-145 were hyper-methylated in tumors compared with matched para-tumor tissues (Fig. 1B,C and Table 1). Meanwhile we investigated the correlation between mean methylation levels of the 300-upstream region and corresponding miR-145 expressions.

---

**Figure 1.** Aberrant hyper-methylation of the CpG sites silences the expression of miR-145 in LAC. (A) Real time-PCR demonstrated expression of miR-145 in three LAC cell lines after treatment with 5-aza-2-deoxycytidine for 3 or 7 days compared with mock-treated cells. Symbol (**) means a significant difference at P < 0.01. (B) Profiling of methylation levels of CpG sites in the miR-145 upstream region was presented as an epigram. (C) Average methylation level of each CpG site in para-tumor tissues and LAC tissues. Symbol (**) means a significant difference at P < 0.01. (D) Correlation analysis between mean methylation levels of the 300-upstream region and corresponding miR-145 expressions.
miR-145 expression as y-axis, a significant negative correlation between the miR-145 expression and methylation levels was observed (Spearman r = −0.7272, p < 0.001; Fig. 1D). Taken together, these data indicated that DNA hyper-methylation in the upstream region of miR-145 might play an important role in the down-regulation of miR-145 in LAC.

Data from TCGA database confirm that DNA methylation is a common mechanism of miR-145 down-regulation in LAC. In consideration of the limited sample size of our study, we tried to dig into the newly available TCGA database for LAC to evaluate whether the depressed miR-145 expressions are in association with elevated DNA methylation. As depicted in Fig. 2A, miR-145 is located in chr5:148810209-148810296. TCGA database included methylation status of three CpG sites in the 5’ end of miR-145 (cg11671363, cg22941668, cg08537847), which are also parts of our assessed 13 CpG sites (Fig. 2A). MethHC (http://MethHC.mbc.nctu.edu.tw) revealed that miR-145 is commonly down-regulated in human LAC accompanied by increased DNA methylation of its 300-upstream region (Fig. 2B). Furthermore, we concretely compared the methylation levels of these three CpG sites between tumor and non-tumor tissues through the data downloaded from Cancer Browser (https://genome-cancer.ucsc.edu/), and the results showed that all of the three CpG sites are hyper-methylated in LAC tissues (Fig. 2C). Therefore, the data from our LAC samples, as well as external LAC cohort (n = 482) at TCGA database, strongly support the point that DNA methylation is a common mechanism of miR-145 down-regulation in LAC.

miR-145 expression level might serve as a novel prognostic biomarker in LAC. To further evaluate the clinical utility of miR-145 in the prognoses of LAC patients, we applied our own LAC tissue microarray containing 92 pairs of LAC and matched non-tumor tissues with long time follow-up records. Expression levels of miR-145 were detected by ISH with probes (Exiqon, Vedbaek, Denmark). As shown in Fig. 3A, we observed that well differentiated LACs showed higher miR-145 expression, as compared with those in poorly differentiated LACs samples. MiR-145 expression in the lymph node metastasis (stage N1-2) and pleural metastasis groups were remarkably lower than those in the non-metastasis groups. Lower miR-145 expression was also correlated with advanced TNM staging (P = 0.025, P = 0.015, P = 0.032, respectively, Fig. 3B). We designated the median miR-145 expression as a cutoff point, and the 92 LAC patients were divided into two groups according the miR-145 expression in tumors: a high miR-145 expression group (n = 46) and a low miR-145 expression group (n = 46). As shown in Table 2, correlation regression analysis indicated that expression of miR-145 was negatively correlated with differentiation (P = 0.011), lymph node metastasis (P = 0.003), pleural invasion (P = 0.035) and TNM

| CpG sites | Number of pairs | Tissue types               | Mean methylation level % (95% CI) |
|-----------|-----------------|-----------------------------|-----------------------------------|
| CpG1      | 20              | para-tumor                  | 13.55 (12.70–14.45)**             |
|           |                 | lung adenocarcinoma tissue  | 19.30 (17.05–21.80)**             |
| CpG2      | 20              | para-tumor                  | 27.65 (25.10–30.10)**             |
|           |                 | lung adenocarcinoma tissue  | 42.85 (36.65–49.75)**             |
| CpG3      | 20              | para-tumor                  | 36.40 (33.70–39.15)**             |
|           |                 | lung adenocarcinoma tissue  | 60.20 (53.20–67.80)**             |
| CpG4      | 20              | para-tumor                  | 28.40 (25.70–31.25)**             |
|           |                 | lung adenocarcinoma tissue  | 42.25 (35.40–49.90)**             |
| CpG5,6    | 20              | para-tumor                  | 28.65 (26.95–30.35)**             |
|           |                 | lung adenocarcinoma tissue  | 41.50 (37.25–45.80)**             |
| CpG7      | 20              | para-tumor                  | 14.40 (13.05–15.80)**             |
|           |                 | lung adenocarcinoma tissue  | 27.75 (23.05–33.20)**             |
| CpG8,9,10 | 20              | para-tumor                  | 55.50 (53.50–57.70)**             |
|           |                 | lung adenocarcinoma tissue  | 76.50 (72.90–79.95)**             |
| CpG11     | 20              | para-tumor                  | 48.10 (46.65–49.60)**             |
|           |                 | lung adenocarcinoma tissue  | 64.20 (61.60–66.80)**             |
| CpG12     | 20              | para-tumor                  | 52.75 (50.10–55.25)**             |
|           |                 | lung adenocarcinoma tissue  | 73.35 (68.05–78.65)**             |
| CpG13     | 20              | para-tumor                  | 45.80 (43.85–47.85)**             |
|           |                 | lung adenocarcinoma tissue  | 58.70 (52.05–65.40)**             |

Table 1. Comparison of methylation level between lung adenocarcinoma and adjacent normal tissue in each CpG site. Symbol (***) means a significant difference at P < 0.01.
staging (P = 0.029). OS and DFS were calculated by Kaplan-Meier analysis and log-rank test. As shown in Fig. 3C-D, patients with lower miR-145 expression exhibited poor OS (HR = 2.128, P = 0.004) and DFS (HR = 2.182, P = 0.003). The univariate and multivariate analysis further revealed that miR-145 expression level was an independent risk factor for both OS and DFS in LAC patients (Fig. 3E-F and Tables 3 and 4). The group with the lower expression of miR-145 also displayed shorter OS and DFS rates (OS: HR = 1.787, 95% CI = 1.021–3.128, p = 0.042; DFS: HR = 1.833, 95% CI = 1.048–3.206, p = 0.034). Collectively, these results indicated that miR-145 expression level might serve as a novel prognostic biomarker in LAC.

Discussion
MiR-145 had been well described to be involved in tumor invasion and progression by targeting c-Myc, AEG-1, EGFR, NUDT1 and OCT4 in LAC15–17, and acknowledged to be a putative tumor-suppressor miRNA. The down-stream mechanisms of miR-145 altering cellular processes were partially confirmed in several published studies. In comparison, the upstream mechanism of which miR-145 was down-regulated in LAC still remained less well understood. Recently, epigenetic silencing of tumor-suppressor miRNA by aberrant DNA hyper-methylation has received increasing attention in a variety of cancers21. To explore the epigenetic mechanism regulating miR-145 in LAC, we compared the expression of miR-145 in three LAC cell lines before and after the treatment of 5-aza-CdR and found that de-methylation treatment induced remarkable miR-145 expression recovery, indicating hyper-methylation plays an important role in the regulation of miR-145 gene expression in LAC. In addition, we assessed the DNA methylation status of 13 CpG sites upstream of miR-145 using MassARRAY-based quantitative methylation analysis in 20 paired LAC and adjacent normal samples. As expected, the results revealed that miR-145 expression is commonly down-regulated in LAC tissues in association with increased DNA methylation, which was further confirmed in a large cohort from TCGA database. As far as we knew that miR-145 was firstly reported to be down-regulated owing to DNA methylation in LAC in our present study.

miRNAs are critical to both physiological and pathological processes, including tumor development and progression22–24. Recently, certain miRNAs are proved to be associated with clinical outcomes in colorectal cancer, pancreatic cancer, breast cancer, and HCC25–28. As a pluripotency repressor, miR-145 directly targets and silences OCT, SOX2 and KLF4 in human embryonic stem cells (ESC), which are required for self-renewal and pluripotency29. The overexpression of OCT4, SOX2, and KLF4 can reprogram or dedifferentiate somatic cells into induced pluripotent stem cells, which resemble the de-differentiation process that cancer cells undergo during tumor formation. Our previous studies also demonstrated that miR-145 suppressed the tumorigenesis and EMT process of LCICs by targeting
Figure 3. Down-regulated expression of miR-145 predicts poor prognosis in LAC patients. 

(A) Representative images of ISH staining of miR-145 in different differentiated LAC tissues from TMA. 

(B) Down-regulation of miR-145 in LAC was associated with clinic-pathological parameters (Pleural invasion, Lymph node metastasis and TNM staging). 

(C,D) The OS and DFS for the high and low miR-145 expression groups were analyzed by the two-sided long-rank test. 

(E,F) A multivariate analysis of the HRs showed that the down-regulation of miR-145 was an independent prognostic factor for the OS and DFS rates (by the Cox multivariate proportional hazard regression model). The HRs are presented as the means (95% CI). The variables included in the multivariate analysis were selected using a univariate analysis.
Oct4.14. Besides, down-regulation of miR-145 was also found to act on other tumor-associated targets such as c-Myc, AEG-1, EGFR, NUDT1 in LAC.15–17. Down-regulated miRNA145 exhibited oncogenic or tumor suppressor properties by regulating multiple mRNAs, highlighting a powerful mechanism for the regulation of tumorigenesis in LAC. Importantly, the novel finding in our present study was that decreased miR-145 level correlated with poor differentiation, lymph node metastasis, pleural invasion, and advanced TNM staging in LAC. Moreover, Kaplan-Meier survival analysis and multivariate analysis revealed that reduced miR-145 level in LAC tumors was an independent predictor of shorter OS and DFS. Based on these results, miR-145 might serve as a potential prognostic marker during the follow up of LAC patients. The results also provided the possibility that miR-145 expression might be used to

| Variable                  | Cases (n) | Expression level of miR-145 | P-value |
|---------------------------|-----------|----------------------------|---------|
|                          | Low (n, %) | High (n, %)                |         |
| Ages                     |           |                            |         |
| < 60                     | 51        | 26 (51.0)                  | 25 (49.0) | 0.834 |
| ≥ 60                     | 41        | 20 (48.8)                  | 21 (51.2) |
| Sex                      |           |                            |         |
| Male                     | 67        | 31 (6.3)                   | 36 (53.7) | 0.241 |
| Female                   | 25        | 15 (60.0)                  | 10 (40.0) |
| Differentiation          |           |                            |         |
| Well                     | 25        | 11 (44.0)                  | 14 (56.0) | 0.011* |
| Moderate                 | 20        | 5 (25.0)                   | 15 (75.0) |
| Poor                     | 47        | 30 (63.8)                  | 17 (36.2) |
| Tumor size               |           |                            |         |
| ≤ 3cm                    | 34        | 13 (38.2)                  | 21 (61.8) | 0.084 |
| > 3cm                    | 58        | 33 (56.9)                  | 25 (43.1) |
| Lymph node metastasis    |           |                            |         |
| No                       | 50        | 18 (36.0)                  | 32 (64.0) | 0.003** |
| Yes                      | 42        | 28 (66.7)                  | 14 (33.3) |
| Pleural invasion         |           |                            |         |
| No                       | 67        | 29 (43.3)                  | 38 (56.7) | 0.035* |
| Yes                      | 25        | 17 (68)                    | 8 (32)  |
| TNM staging              |           |                            |         |
| I                        | 34        | 11 (32.3)                  | 23 (67.6) | 0.029* |
| II                       | 25        | 14 (56.0)                  | 11 (44.0) |
| III                      | 33        | 21 (63.6)                  | 12 (36.4) |

Table 3. Univariate and multivariate Cox regression analyses of overall survival in 92 NSCLC patients following surgery.
design optimal treatment for LAC patients, for instance, distinguishing locally advanced LAC patients
who would benefit much from surgery.

In conclusion, our present study demonstrates that miR-145, which is regulated by DNA methylation,
might be a valuable prognostic marker in LAC patients.

Materials and Methods

Patient samples and TMA. For methylation analysis, 22 freshly resected LAC specimens and their
adjacent normal lung tissues were collected from the department of thoracic surgery, Cancer Institute of
Jiangsu Province, China. The specimens were snap-frozen in liquid nitrogen.

TMA was performed to evaluate the clinical utility of miR-145 as a prognostic marker. Briefly,
formalin-fixed paraffin-embedded archive tissues of 92 paired LAC and adjacent normal lung tissues
were arranged in tissue array blocks (Shanghai Biochip Co., Ltd. Shanghai, China). Each tissue spot was
accompanied with cases material including sex, age, pathologic type, pathologic grade and clinical stage.
The study was in accordance with the provisions of Ethics Committee of Nanjing Medical University. A
written informed consent was obtained from all participants involved in this study.

Cell culture and treatment with 5-Aza-CdR. Human LAC cell lines A549, H1299 and SPC-A-1
purchased from American Type Culture Collection (ATCC, USA) were maintained in RPMI 1640
(Hyclone, Logan, UT) and supplemented with 10% fetal bovine serum (FBS, Invitrogen) at 37 °C in
the humidified atmosphere with 5% CO2. After serum starvation for 24 hours, three LAC cancer cell
lines were seeded in six-well plates, allowed to attach for 3, 7 days and treated with 0, 5 and 10μM of
5-Aza-CdR, respectively.

RNA extraction and RT-PCR. Total RNA was extracted from cell lines and tissues using mirVana
RNNA Isolation Kit (Applied Biosystems). Mature miR-145 levels were quantified using TaqMan
microRNA Assay (Applied Biosystems). Quantification was normalized to the U6 small nuclear B
non-coding RNNA (RNRNU6B, Applied Biosystems), which served as an endogenous control. The
ΔΔCT method was used to calculate the CT-value for each sample, and the results were expressed as
2−ΔΔCT to analyze the fold change (tumor vs. normal):

Table 4. Univariate and multivariate Cox regression analyses of disease-free survival in 92 NSCLC
patients following surgery.

| Parameters                      | Univariate analysis | Multivariable analysis |
|---------------------------------|---------------------|------------------------|
|                                 | HR                  | 95% CI                 | P value   | HR                  | 95% CI                 | P value   |
| Age (> 60)                      | 1.917               | 1.144–3.213            | 0.014     | 1.863               | 1.076–3.226            | 0.026     |
| Gender (male)                   | 1.070               | 0.603–1.901            | 0.816     | —                   | —                     | —         |
| Tumor diameter (> 3 cm)         | 1.113               | 0.653–1.897            | 0.695     | —                   | —                     | —         |
| Pleural invasion (Positive)     | 1.631               | 0.950–2.800            | 0.078     | —                   | —                     | —         |
| Lymph node metastasis (Positive) | 2.402               | 1.430–4.033            | 0.001     | 1.499               | 0.802–2.802            | 0.205     |
| TNM stage (II and III)          | 2.286               | 1.367–3.823            | 0.002     | 1.536               | 0.847–2.785            | 0.158     |
| Histologic grade (M-L and L)    | 2.499               | 1.415–4.411            | 0.002     | 1.714               | 0.937–3.135            | 0.080     |
| miR-145 level (Low)             | 2.182               | 1.286–3.701            | 0.003     | 1.833               | 1.048–3.206            | 0.034     |

DNA extraction and methylation analyses. Genomic DNA was extracted from 22 resected
LAC specimens and their adjacent normal lung tissues using the genomic DNA rapid extraction kit
(TIANGEN BIOTECH CO, LTD. Beijing, China). The quality and quantified were evaluated by gel
electrophoresis and a NanoDrop spectrophotometer (GE Healthcare Life Sciences, Uppsala, Sweden),
2 of the 22 paired samples are not qualified. The genomic DNA from each sample was treated with
sodium bisulfite using an EZ DNA methylation kit (Zymo Research, Orange, CA). The Sequenom
MassARRAY platform (CapitalBio, Beijing, China) was used for quantitative analysis of miR-145 methylation.
This system employs matrix-assisted laser-desorption/ionization time-of-flight mass spectrometry.
in combination with RNA base-specific cleavage. We used the following two pairs of primers on the basis of the reverse complemented strand of miR-145, (aggaagagAGGTTAAGGTTTAGGGGTTAA-GTGA, cagtaactagcactatagagagactgctACATCCAACCCCATCTAAACAA) to amplify base pairs -354 – (−62) upstream of miR-145, (aggaagagGTTGTTTAGAGATGGGGTTGGATGTA, cagtaactagcactatagagagactgCTCTATCCCTCAAAAAACGTTTCT) to amplify base pairs -87 - (+195) around miR-145. For each reverse primer, an additional T7 promoter tag (5′-cagtaatacgactcactatagggagaaggct-3′) around +195 around the T7 promoter tag (5′-cagtaatacgactcactatagggagaaggctCAGTTAAGGTTTAGGGTAA-GTGA, cagtaactagcactatagagagactgctACATCCAACCCCATCTAAACAA) to amplify base pairs -354 – (−62) upstream of miR-145, (aggaagagGTTGTTTAGAGATGGGGTTGGATGTA, cagtaactagcactatagagagactgCTCTATCCCTCAAAAAACGTTTCT) to amplify base pairs -87 - (+195) around miR-145. For each reverse primer, an additional T7 promoter tag (5′-cagtaatacgactcactatagggagaaggct-3′) for in vitro transcription was added. In addition, a 10-mer tag (5′-aggaagag-3′) was added on each forward primer to adjust for melting-temperature differences between the forward and reverse primers. Altogether, 13 CpG sites were tested in this region. The spectra methylation ratios for each CpG site were generated by Epityper software version 1.0 (Sequenom).

In situ hybridization (ISH). Expression of miR-145 in 92 pairs of LAC tissues were detected by ISH with probes for miR-145 (Exiqon, Vedbaek, Denmark). The 5′-3′ sequences (enhanced with LNA) were AGAACAGTATTTCCAGGAATCC with a DIG label at both the 5′ and 3′ ends. The TMA was in an oven at 60 °C for 60 mins then stored as slides overnight at 4 °C. Deparaffinized slides were in xylene and ethanol solutions at room temperature and then incubated with Proteinase-K for 7.5 mins at 37°C. Slides were hybridized with 1000 nmol/L miR-145 probe in a hybridization buffer for 20 min at 50°C then washed with SSC buffers. The remaining procedures were performed with a modified version of the manufacturer’s protocol. The intensity of miR-145 staining was scored by 0–2, according to the standards of 0–0.5 (weak staining), 0.5–1.5 (medium staining) and 1.5–2 (strong staining). Those expression scores were figured out by the intensities x the percentages of positive cells. In a blind method, individual specimens were evaluated by two pathologists, and those with scores of greater than 0.5 were defined as high expression, less than or equal to 0.5 were low expressions.

Statistical analysis. All statistical analyses were performed using SPSS version 19.0 software (SPSS Inc., Chicago, USA). Student’s t-test and paired t-test were applied to evaluate methylation level of miR-145. A linear regression was performed to infer the correlation between the methylation percentage and expression of miR-145. The associations between clinical characteristics and miR-145 expressions were analyzed by the chi² test. Survival curves were plotted using the Kaplan–Meier method, and differences between survival curves were tested using the log-rank test. Cox’s proportional hazards model was used to identify the factors that have significantly independent influence on survival. Statistical significance was set at P < 0.05.

References
1. Jemal, A. et al. Global cancer statistics. CA: a cancer journal for clinicians 61, 69–90, doi: 10.3322/caac.20107 (2011).
2. Spira, A. & Ettinger, D. S. Multidisciplinary management of lung cancer. The New England journal of medicine 350, 379–392, doi: 10.1056/NEJMra035536 (2004).
3. Landi, M. T. et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 16, 430–441, doi: 10.1158/1078-0432.CCR-09-1736 (2010).
4. Yu, S. L. et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer cell 13, 48–57, doi: 10.1016/j. ccres.2007.12.008 (2008).
5. Yamahara, N. et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer cell 9, 189–198, doi: 10.1016/j.ccr.2006.01.025 (2006).
6. Vossa, U. et al. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer. Genes, chromosomes & cancer 50, 812–822, doi: 10.1002/gcc.20902 (2011).
7. Porkka, K. P. et al. MicroRNA expression profiling in prostate cancer. Cancer research 67, 6130–6135, doi: 10.1158/0008-5472. CAN-07-0533 (2007).
8. Ichimi, T. et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. International journal of cancer. Journal international du cancer 125, 345–352, doi: 10.1002/ijc.24390 (2009).
9. Akao, Y., Nakagawa, Y. & Naoe, T. MicroRNA-143 and -145 in colon cancer. DNA and cell biology 26, 311–320, doi: 10.1089/ dna.2006.0530 (2007).
10. Sachdeva, M. et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proceedings of the National Academy of Sciences of the United States of America 106, 3207–3212, doi: 10.1073/pnas.0808042106 (2009).
11. Slaby, O. et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72, 397–402, doi: 10.1159/000133489 (2007).
12. Nam, E. et al. MicroRNA expression profiles in serous ovarian carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 14, 2690–2695, doi: 10.1158/1078-0432.CCR-07-1731 (2008).
13. Yin, R. et al. microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4. Oncology reports 25, 1747–1754, doi: 10.3892/or.2011.1252 (2011).
14. Hu, J. et al. microRNAs-145 regulates cancer stem-like properties and epithelial-to-mesenchymal transition in lung adenocarcinoma-initiating cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 35, 8953–8961, doi: 10.4103/2105-3770.121588 (2014).
15. Chen, Z. et al. miR-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. Journal of experimental & clinical cancer research : CR 29, 151, doi: 10.1186/1756-9966-29-151 (2010).
16. Cho, W. C., Chow, A. S. & Au, J. S. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT11. RNA biology 8, 123–131 (2011).
17. Wang, M. et al. MiR-145 acts as a metastasis suppressor by targeting metadherin in lung cancer. Medical oncology 32, 344, doi: 10.1007/s12323-014-0344-6 (2015).
18. Saito, Y. & Jones, P. A. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell cycle 5, 2220–2222 (2006).
19. Lujambio, A. & Esteller, M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell cycle 6, 1455–1459 (2007).
20. Lopez-Serra, P. & Esteller, M. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 31, 1609–1622, doi: 10.1038/onc.2011.354 (2012).
21. Xie, K. et al. Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer. Gene 543, 101–107, doi: 10.1016/j.gene.2014.03.059 (2014).
22. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004).
23. Xu, L. et al. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity. Journal of hepatology 60, 590–598, doi: 10.1016/j.jhep.2013.10.028 (2014).
24. Brockhausen, J. et al. miR-181a mediates TGF-beta-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer. Liver international: official journal of the International Association for the Study of the Liver 35, 240–253, doi: 10.1111/liv.12517 (2015).
25. Shibuya, H., Inuma, H., Shimada, R., Horiiuchi, A. & Watanabe, T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology 79, 313–320, doi: 10.1159/000323283 (2010).
26. Bloomston, M. et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. Jama 297, 1901–1908, doi: 10.1001/jama.297.17.1901 (2007).
27. Iorio, M. V. et al. MicroRNA gene expression deregulation in human breast cancer. Cancer research 65, 7065–7070, doi: 10.1158/0008-5472.CAN-05-1783 (2005).
28. Budhu, A. et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47, 897–907, doi: 10.1002/hep.22160 (2008).
29. Xu, N., Papagiannakopoulos, T., Pan, G., Thomson, J. A. & Kosik, K. S. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137, 647–658, doi: 10.1016/j.cell.2009.02.038 (2009).

Acknowledgements
This work was supported by the Natural Science Foundation of Jiangsu Province [grant number: BK2012482], National Natural Science Foundation of China [grant number: 81472702] and Jiangsu Provincial Special Program of Medical Science [grant number. BL2012030].

Author Contributions
W.X., J.W., Q.M. and R.S. carried on the main experiment. Q.C. and G.D. performed the data analysis. W.X. and Y.Y.Z. wrote the main manuscript text. F.J. prepared the figures. L.X. checked and revised the paper at last. All authors reviewed the manuscript.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Xia, W. et al. DNA methylation mediated silencing of microRNA-145 is a potential prognostic marker in patients with lung adenocarcinoma. Sci. Rep. 5, 16901; doi: 10.1038/srep16901 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/